Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6817)
All Articles published online
|
Publishing Process of This Article
|
Jun 14, 2017 (publication date) through May 7, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bennett RG, Simpson RL, Hamel FG. Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis. World J Gastroenterol 2017; 23(22): 3999-4006 [PMID: 28652653 DOI: 10.3748/wjg.v23.i22.3999] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i22/3999.htm |
| Number | Citing Articles |
| 1 |
Benita L. McVicker, Ronda L. Simpson, Frederick G. Hamel, Robert G. Bennett. Reduction in Obesity-Related Hepatic Fibrosis by SR1664. Biology 2023; 12(10): 1287 doi: 10.3390/biology12101287
|
| 2 |
Tobias Puengel, Frank Tacke. Sinusoidal Cells in Liver Diseases. 2024; : 483 doi: 10.1016/B978-0-323-95262-0.00024-3
|
| 3 |
Kateryna Levada, Alexander Omelyanchik, Valeria Rodionova, Ralf Weiskirchen, Matthias Bartneck. Magnetic-Assisted Treatment of Liver Fibrosis. Cells 2019; 8(10): 1279 doi: 10.3390/cells8101279
|
| 4 |
Devaraj Ezhilarasan. Relaxin in hepatic fibrosis: What is known and where to head?. Biochimie 2021; 187: 144 doi: 10.1016/j.biochi.2021.06.001
|
| 5 |
Benita L. McVicker, Frederick G. Hamel, Ronda L. Simpson, Robert G. Bennett. A Selective PPARγ Modulator Reduces Hepatic Fibrosis. Biology 2020; 9(7): 151 doi: 10.3390/biology9070151
|
| 6 |
Siyer Roohani, Frank Tacke. Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance. International Journal of Molecular Sciences 2021; 22(14): 7249 doi: 10.3390/ijms22147249
|
| 7 |
Aziz Eftekhari, Allahveirdy Arjmand, Ayyub Asheghvatan, Helena Švajdlenková, Ondrej Šauša, Huseyn Abiyev, Elham Ahmadian, Oleh Smutok, Rovshan Khalilov, Taras Kavetskyy, Magali Cucchiarini. The Potential Application of Magnetic Nanoparticles for Liver Fibrosis Theranostics. Frontiers in Chemistry 2021; 9 doi: 10.3389/fchem.2021.674786
|
| 8 |
Yankai Wen, Joeri Lambrecht, Cynthia Ju, Frank Tacke. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cellular & Molecular Immunology 2021; 18(1): 45 doi: 10.1038/s41423-020-00558-8
|
| 9 |
Kyeong-Jin Lee, Mi-Yeon Kim, Yong-Hyun Han. Roles of heterogenous hepatic macrophages in the progression of liver diseases. BMB Reports 2022; 55(4): 166 doi: 10.5483/BMBRep.2022.55.4.022
|
| 10 |
Xueping Wu, Yehui Lv, Zhihong Li, Zhifang Yang. Serelaxin Inhibits Lipopolysaccharide-induced Inflammatory Response in Cardiac Fibroblasts by Activating Peroxisome Proliferator-activated Receptor-γ and Suppressing the Nuclear Factor-Kappa B Signaling Pathway. Journal of Cardiovascular Pharmacology 2023; 82(3): 201 doi: 10.1097/FJC.0000000000001447
|
| 11 |
Shuai Yuan, Dong Guo, Xinzhi Liang, Luhui Zhang, Qun Zhang, Denghui Xie. Relaxin in fibrotic ligament diseases: Its regulatory role and mechanism. Frontiers in Cell and Developmental Biology 2023; 11 doi: 10.3389/fcell.2023.1131481
|
| 12 |
Chrishan S. Samuel, Robert G. Bennett. Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directions. Biochemical Pharmacology 2022; 197: 114884 doi: 10.1016/j.bcp.2021.114884
|
| 13 |
Joeri Lambrecht, Leo A. van Grunsven, Frank Tacke. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opinion on Pharmacotherapy 2020; 21(13): 1637 doi: 10.1080/14656566.2020.1774553
|
| 14 |
Kaveh Baghaei, Sogol Mazhari, Samaneh Tokhanbigli, Gilda Parsamanesh, Helia Alavifard, Dedmer Schaafsma, Saeid Ghavami. Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis. Drug Discovery Today 2022; 27(4): 1044 doi: 10.1016/j.drudis.2021.12.012
|
| 15 |
Anne Geng, Emilio Flint, Christine Bernsmeier. Plasticity of monocytes and macrophages in cirrhosis of the liver. Frontiers in Network Physiology 2022; 2 doi: 10.3389/fnetp.2022.937739
|
| 16 |
Robert G. Bennett. Targeting the Relaxin Pathway for Liver Disease Treatment. EMJ Hepatology 2018; : 80 doi: 10.33590/emjhepatol/10311638
|
| 17 |
Lijuan Xiong, Kexin Lin, Tianmu He, Xingyan Liu, Rui Yuan, Xiaofei Li, Jianyong Zhang. A novel approach combining network pharmacology and experimental validation to study the protective effect of ginsenoside Rb1 against cantharidin‐induced hepatotoxicity in mice. Basic & Clinical Pharmacology & Toxicology 2024; 134(5): 737 doi: 10.1111/bcpt.13999
|
| 18 |
Honglei Zhang, Lin You, Min Zhao. Rosiglitazone attenuates paraquat-induced lung fibrosis in rats in a PPAR gamma-dependent manner. European Journal of Pharmacology 2019; 851: 133 doi: 10.1016/j.ejphar.2019.02.037
|
| 19 |
Adam L. Valkovic, Ross AD. Bathgate, Chrishan S. Samuel, Martina Kocan. Understanding relaxin signalling at the cellular level. Molecular and Cellular Endocrinology 2019; 487: 24 doi: 10.1016/j.mce.2018.12.017
|
| 20 |
Eric Kalo, Scott Read, Golo Ahlenstiel. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021; 1(3): 147 doi: 10.3390/livers1030014
|
| 21 |
Brigitte Grouix, Francois Sarra-Bournet, Martin Leduc, Jean-Christophe Simard, Kathy Hince, Lilianne Geerts, Alexandra Blais, Liette Gervais, Alexandre Laverdure, Alexandra Felton, Jonathan Richard, Jugurtha Ouboudinar, William Gagnon, François A. Leblond, Pierre Laurin, Lyne Gagnon. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway. Journal of Pharmacology and Experimental Therapeutics 2018; 367(1): 71 doi: 10.1124/jpet.118.250068
|
| 22 |
Xu Li, Yuan Jiao, Yunlong Xing, Pujun Gao. Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis. BioMed Research International 2019; 2019: 1 doi: 10.1155/2019/5308308
|
| 23 |
Shao-ce Zhi, Shi-zuan Chen, Yan-yan Li, Jun-jian Li, Yi-hu Zheng, Fu-xiang Yu. RETRACTED ARTICLE: Rosiglitazone Inhibits Activation of Hepatic Stellate Cells via Up-Regulating Micro-RNA-124-3p to Alleviate Hepatic Fibrosis. Digestive Diseases and Sciences 2019; 64(6): 1560 doi: 10.1007/s10620-019-5462-8
|
| 24 |
Arjuna Singanayagam, Evangelos Triantafyllou. Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.661182
|